<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369796</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-448-2001</org_study_id>
    <secondary_id>U1111-1162-4892</secondary_id>
    <secondary_id>2014-002155-25</secondary_id>
    <secondary_id>14/LO/1950</secondary_id>
    <nct_id>NCT02369796</nct_id>
  </id_info>
  <brief_title>A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism</brief_title>
  <official_title>An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Participants With Hypogonadotropic Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects on serum testosterone after 4 weeks of
      subcutaneous (SC) dose administration, with different doses and dosing frequencies of TAK-448
      to overweight/obese males with hypogonadotropic hypogonadism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-448. TAK-448 is being tested to treat
      overweight/obese males with hypogonadotropic hypogonadism. This study will look at the
      effects of TAK-448 on serum testosterone at different doses and different dosing frequencies.

      The study will enroll 15 patients. There will be 5 cohorts and participants will be assigned
      to cohorts in sequential order. Cohorts will be assigned to the following treatment groups:

        -  TAK-448 3 µg once weekly

        -  TAK-448 1 µg once weekly

        -  TAK-448 0.3 µg once weekly

        -  TAK-448 0.3 µg twice weekly

        -  TAK-448 0.1 µg twice weekly

      All participants will be administered study drug via SC injection once or twice a week
      depending on their assigned cohort for four weeks.

      This single-center trial will be conducted in the United Kingdom. The overall time to
      participate in this study is up to 32 days. Participants will make multiple visits to the
      clinic (depending once-weekly or twice-weekly dosing), and will be contacted by telephone 1
      week after last dose of study drug for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision to terminate the study because the study did not achieve the primary efficacy
    objective.
  </why_stopped>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Total Serum Testosterone for Once Weekly Dosing Groups</measure>
    <time_frame>Baseline and Day 22 pre-dose and multiple time points (up to 72 hours) post dose</time_frame>
    <description>Area under the pharmacodynamic (PD) total serum testosterone (ST) concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Total Serum Testosterone for Twice Weekly Dosing Groups</measure>
    <time_frame>Baseline and Day 25 pre-dose and multiple time points (up to 72 hours) post dose</time_frame>
    <description>Area under the PD total ST concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Free Serum Testosterone for Once Weekly Dosing Groups</measure>
    <time_frame>Baseline and Day 22 pre-dose and multiple time points (up to 72 hours) post dose</time_frame>
    <description>Area under the PD free ST concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Free Serum Testosterone for Twice Weekly Dosing Groups</measure>
    <time_frame>Baseline and Day 25 pre-dose and multiple time points (up to 72 hours) post dose</time_frame>
    <description>Area under the PD free ST concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Serum Concentration (Ctrough) of Total Serum Testosterone for Once Weekly Dosing Groups</measure>
    <time_frame>Day 22 pre-dose</time_frame>
    <description>Trough serum concentration of total ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Serum Concentration (Ctrough) of Total Serum Testosterone for Twice Weekly Dosing Group</measure>
    <time_frame>Day 25 pre-dose</time_frame>
    <description>Trough serum concentration of total ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Serum Concentration (Ctrough) of Free Serum Testosterone for Once Weekly Dosing Groups</measure>
    <time_frame>Day 22 pre-dose</time_frame>
    <description>Trough serum concentration of free ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Serum Concentration (Ctrough) of Free Serum Testosterone for Twice Weekly Dosing Groups</measure>
    <time_frame>Day 25 pre-dose</time_frame>
    <description>Trough serum concentration of free ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Mean Maximum Observed Plasma Concentration for TAK-448 Free Base Form (TAK-448F)</measure>
    <time_frame>Day 1 and Day 22 pre-dose and at multiple time points (up to 8 hours) post-dose</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-∞): Mean Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-448F</measure>
    <time_frame>Day 1 and Day 22 pre-dose and at multiple time points (up to 8 hours) post-dose</time_frame>
    <description>AUC(0-∞) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlqc): Mean Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-448F</measure>
    <time_frame>Day 1 and Day 22 pre-dose and at multiple time points (up to 8 hours) post-dose</time_frame>
    <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Terminal Phase Elimination Half-life (T1/2) for TAK-448F</measure>
    <time_frame>Day 1 and Day 22 pre-dose and at multiple time points (up to 8 hours) post-dose</time_frame>
    <description>Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hypogonadotropic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>TAK-448 3 µg once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-448 1 µg once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-448 0.3 µg once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-448 0.3 µg twice weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-448 0.1 µg twice weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-448</intervention_name>
    <description>TAK-448 solution for subcutaneous injection</description>
    <arm_group_label>TAK-448 3 µg once weekly</arm_group_label>
    <arm_group_label>TAK-448 1 µg once weekly</arm_group_label>
    <arm_group_label>TAK-448 0.3 µg once weekly</arm_group_label>
    <arm_group_label>TAK-448 0.3 µg twice weekly</arm_group_label>
    <arm_group_label>TAK-448 0.1 µg twice weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          2. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          3. The participant has two morning total serum testosterone (ST) concentrations ≤12.0
             nmol/L (≤3.46 ng/mL) taken during the Screening period.

          4. Is male and aged 18 to 60 years, inclusive.

          5. Has a body mass index (BMI) between 25.0 and 50.0 kg/m^2, inclusive.

          6. If diagnosed with type II diabetes mellitus (T2DM), has a glycosylated hemoglobin
             (HbA1c) concentration &lt;12% at Screening and is on a stable dose of up to 4 diabetes
             therapies (including insulin and/or glucagon-like peptide-1 therapies).

          7. Has a luteinizing hormone (LH) concentration &lt;8 IU/L at Screening.

          8. A male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 12 weeks after last dose.

        Exclusion Criteria:

          1. Has received any investigational compound within 30 days prior to Screening.

          2. Has received TAK-448 in a previous clinical study, or previous cohort.

          3. Is an immediate family member, study site employee, or is in a dependant relationship
             with a study site employee who is involved in conduct of this study (eg, spouse,
             parent, child, sibling) or may consent under duress.

          4. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary,
             hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality
             (other than T2DM, its complications and associated conditions), which may impact the
             ability of the participant to participate or potentially confound the study results.

          5. Has a recent history or clinical manifestations of significant cardiovascular disease
             (CVD) - such as a history of myocardial infarction or stroke in the 6 months preceding
             the Screening visit or has untreated peripheral arterial disease.

          6. Has a history of hypersensitivity or allergies to any component of the formulation of
             TAK-448.

          7. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse within 5 years prior to Screening.

          8. Is required to take excluded medications, supplements, or food products.

          9. Intends to donate sperm during the course of this study or for 12 weeks after the last
             dose of study drug.

         10. Has clinical evidence of anatomic or pathological hypothalamic/pituitary disease.

         11. Is any finding in the participant's medical history, physical examination, or safety
             laboratory tests giving reasonable suspicion of a disease that would contraindicate
             taking TAK-448, or a similar drug in the same class that might interfere with the
             conduct of the study.

         12. Has a history of cancer (including prostate cancer), with the exception of basal cell
             carcinoma which has been in remission for at least 5 years prior to Screening.

         13. Has a history of or present prostate disease (including benign prostatic hyperplasia)
             or prostate-specific antigen (PSA) is &gt;4 ng/mL at Screening.

         14. Has a known history of human immunodeficiency virus infection at Screening.

         15. Is deemed by the study team to have poor peripheral venous access.

         16. Has donated or lost 450 mL or more of his blood volume (including plasmapheresis), or
             had a transfusion of any blood product within 45 days prior to Screening, or is
             planning to donate blood for 12 weeks after the last dose of study medication.

         17. Has a Screening or Day -1 abnormal (clinically significant) electrocardiogram (ECG).
             Entry of any participant with an abnormal (not clinically significant) ECG must be
             approved, and documented by signature of the principal investigator or medically
             qualified subinvestigator.

         18. Has abnormal Screening or Day -1 laboratory values that suggest a clinically
             significant underlying disease or participant with the following lab abnormalities:
             alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt;2× the upper
             limits of normal (ULN).

         19. The participant, in the opinion of the investigator, is unlikely to comply with the
             protocol or is unsuitable for any other reason.

         20. Has had more than two severe hypoglycemic events (requiring third party assistance)
             within 6 months prior to the Screening Visit.

         21. Has a diagnosis of type 1 diabetes mellitus.

         22. Has a history of diabetic ketoacidosis.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <results_first_submitted>November 1, 2016</results_first_submitted>
  <results_first_submitted_qc>February 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2017</results_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United Kingdom from 10 February 2015 to 3 November 2015.</recruitment_details>
      <pre_assignment_details>Overweight/obese male participants with a diagnosis of hypogonadotropic hypogonadism were enrolled in 1 of 5 treatment groups: once weekly TAK-448 3 µg, 1 µg or 0.3 µg or twice weekly TAK-448 0.3 µg or 0.1 µg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAK-448 3 µg Once Weekly</title>
          <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
        </group>
        <group group_id="P2">
          <title>TAK-448 1 µg Once Weekly</title>
          <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
        </group>
        <group group_id="P3">
          <title>TAK-448 0.3 µg Once Weekly</title>
          <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
        </group>
        <group group_id="P4">
          <title>TAK-448 0.3 µg Twice Weekly</title>
          <description>TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
        </group>
        <group group_id="P5">
          <title>TAK-448 0.1 µg Twice Weekly</title>
          <description>TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all participants who were enrolled and received at least 1 dose of study drug, including participants who did not complete all scheduled study visits.</population>
      <group_list>
        <group group_id="B1">
          <title>TAK-448 3 µg Once Weekly</title>
          <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
        </group>
        <group group_id="B2">
          <title>TAK-448 1 µg Once Weekly</title>
          <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
        </group>
        <group group_id="B3">
          <title>TAK-448 0.3 µg Once Weekly</title>
          <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
        </group>
        <group group_id="B4">
          <title>TAK-448 0.3 µg Twice Weekly</title>
          <description>TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
        </group>
        <group group_id="B5">
          <title>TAK-448 0.1 µg Twice Weekly</title>
          <description>TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="8.02"/>
                    <measurement group_id="B2" value="50.7" spread="4.62"/>
                    <measurement group_id="B3" value="51.7" spread="3.79"/>
                    <measurement group_id="B4" value="56.0" spread="3.61"/>
                    <measurement group_id="B5" value="45.0" spread="19.16"/>
                    <measurement group_id="B6" value="50.8" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168" spread="7"/>
                    <measurement group_id="B2" value="174" spread="6"/>
                    <measurement group_id="B3" value="181" spread="18"/>
                    <measurement group_id="B4" value="178" spread="6"/>
                    <measurement group_id="B5" value="178" spread="12"/>
                    <measurement group_id="B6" value="176" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104" spread="30"/>
                    <measurement group_id="B2" value="113" spread="10"/>
                    <measurement group_id="B3" value="119" spread="26"/>
                    <measurement group_id="B4" value="115" spread="7"/>
                    <measurement group_id="B5" value="110" spread="26"/>
                    <measurement group_id="B6" value="112" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="8"/>
                    <measurement group_id="B2" value="37" spread="1"/>
                    <measurement group_id="B3" value="36" spread="2"/>
                    <measurement group_id="B4" value="36" spread="2"/>
                    <measurement group_id="B5" value="34" spread="4"/>
                    <measurement group_id="B6" value="36" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Has never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Is current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Is an ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Has never drunk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Is current drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Is an ex-drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Consumption</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Total Serum Testosterone for Once Weekly Dosing Groups</title>
        <description>Area under the pharmacodynamic (PD) total serum testosterone (ST) concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
        <time_frame>Baseline and Day 22 pre-dose and multiple time points (up to 72 hours) post dose</time_frame>
        <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 3 µg Once Weekly</title>
            <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 1 µg Once Weekly</title>
            <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 0.3 µg Once Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Total Serum Testosterone for Once Weekly Dosing Groups</title>
          <description>Area under the pharmacodynamic (PD) total serum testosterone (ST) concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
          <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="11.3"/>
                    <measurement group_id="O2" value="13.5" spread="24.9"/>
                    <measurement group_id="O3" value="14.9" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Total Serum Testosterone for Twice Weekly Dosing Groups</title>
        <description>Area under the PD total ST concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
        <time_frame>Baseline and Day 25 pre-dose and multiple time points (up to 72 hours) post dose</time_frame>
        <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 0.3 µg Twice Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 0.1 µg Twice Weekly</title>
            <description>TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Total Serum Testosterone for Twice Weekly Dosing Groups</title>
          <description>Area under the PD total ST concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
          <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="3.7"/>
                    <measurement group_id="O2" value="6.0" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Free Serum Testosterone for Once Weekly Dosing Groups</title>
        <description>Area under the PD free ST concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
        <time_frame>Baseline and Day 22 pre-dose and multiple time points (up to 72 hours) post dose</time_frame>
        <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 3 µg Once Weekly</title>
            <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 1 µg Once Weekly</title>
            <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 0.3 µg Once Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Free Serum Testosterone for Once Weekly Dosing Groups</title>
          <description>Area under the PD free ST concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
          <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="9.08"/>
                    <measurement group_id="O2" value="11.1" spread="28.0"/>
                    <measurement group_id="O3" value="7.92" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Free Serum Testosterone for Twice Weekly Dosing Groups</title>
        <description>Area under the PD free ST concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
        <time_frame>Baseline and Day 25 pre-dose and multiple time points (up to 72 hours) post dose</time_frame>
        <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 0.3 µg Twice Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 0.1 µg Twice Weekly</title>
            <description>TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Free Serum Testosterone for Twice Weekly Dosing Groups</title>
          <description>Area under the PD free ST concentration-time curve from the time 0 to 72 hours, calculated using the linear trapezoidal rule for baseline profile and those obtained after first and last dose.</description>
          <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.00" spread="4.23"/>
                    <measurement group_id="O2" value="20.5" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough Serum Concentration (Ctrough) of Total Serum Testosterone for Once Weekly Dosing Groups</title>
        <description>Trough serum concentration of total ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
        <time_frame>Day 22 pre-dose</time_frame>
        <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 3 µg Once Weekly</title>
            <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 1 µg Once Weekly</title>
            <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 0.3 µg Once Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Serum Concentration (Ctrough) of Total Serum Testosterone for Once Weekly Dosing Groups</title>
          <description>Trough serum concentration of total ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
          <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.3"/>
                    <measurement group_id="O2" value="4.4" spread="3.1"/>
                    <measurement group_id="O3" value="8.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough Serum Concentration (Ctrough) of Total Serum Testosterone for Twice Weekly Dosing Group</title>
        <description>Trough serum concentration of total ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
        <time_frame>Day 25 pre-dose</time_frame>
        <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 0.3 µg Twice Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 0.1 µg Twice Weekly</title>
            <description>TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Serum Concentration (Ctrough) of Total Serum Testosterone for Twice Weekly Dosing Group</title>
          <description>Trough serum concentration of total ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
          <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="2.8"/>
                    <measurement group_id="O2" value="6.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough Serum Concentration (Ctrough) of Free Serum Testosterone for Once Weekly Dosing Groups</title>
        <description>Trough serum concentration of free ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
        <time_frame>Day 22 pre-dose</time_frame>
        <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure. Number of participants analyzed is number of participants evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 3 µg Once Weekly</title>
            <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 1 µg Once Weekly</title>
            <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 0.3 µg Once Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Serum Concentration (Ctrough) of Free Serum Testosterone for Once Weekly Dosing Groups</title>
          <description>Trough serum concentration of free ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
          <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure. Number of participants analyzed is number of participants evaluated for this outcome measure.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.03"/>
                    <measurement group_id="O2" value="0.12" spread="0.07"/>
                    <measurement group_id="O3" value="0.21" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough Serum Concentration (Ctrough) of Free Serum Testosterone for Twice Weekly Dosing Groups</title>
        <description>Trough serum concentration of free ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
        <time_frame>Day 25 pre-dose</time_frame>
        <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 0.3 µg Twice Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 0.1 µg Twice Weekly</title>
            <description>TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Serum Concentration (Ctrough) of Free Serum Testosterone for Twice Weekly Dosing Groups</title>
          <description>Trough serum concentration of free ST, defined as lowest baseline concentration compared to pre-dose of the last dose.</description>
          <population>PD set included all participants who received at least one dose of study drug and had at least 1 valid PD measure.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.09"/>
                    <measurement group_id="O2" value="0.20" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Mean Maximum Observed Plasma Concentration for TAK-448 Free Base Form (TAK-448F)</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Day 1 and Day 22 pre-dose and at multiple time points (up to 8 hours) post-dose</time_frame>
        <population>Pharmacokinetic (PK) set included all participants who received at least one dose of study drug and had at least 1 measurable concentration of TAK-448F.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 3 µg Once Weekly</title>
            <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 1 µg Once Weekly</title>
            <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 0.3 µg Once Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Mean Maximum Observed Plasma Concentration for TAK-448 Free Base Form (TAK-448F)</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>Pharmacokinetic (PK) set included all participants who received at least one dose of study drug and had at least 1 measurable concentration of TAK-448F.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.50" spread="4.943"/>
                    <measurement group_id="O2" value="10.46" spread="1.484"/>
                    <measurement group_id="O3" value="NA">Data was not estimable as plasma concentration was below the lower level of quantification (LLOQ).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.10" spread="6.344"/>
                    <measurement group_id="O2" value="12.27" spread="3.618"/>
                    <measurement group_id="O3" value="NA">Data was not estimable as plasma concentration was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-∞): Mean Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-448F</title>
        <description>AUC(0-∞) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
        <time_frame>Day 1 and Day 22 pre-dose and at multiple time points (up to 8 hours) post-dose</time_frame>
        <population>PK set included all participants who received at least one dose of study drug and had at least 1 measurable concentration of TAK-448F. Here, 'n' is the participants who were analyzed at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 3 µg Once Weekly</title>
            <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 1 µg Once Weekly</title>
            <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 0.3 µg Once Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-∞): Mean Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-448F</title>
          <description>AUC(0-∞) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
          <population>PK set included all participants who received at least one dose of study drug and had at least 1 measurable concentration of TAK-448F. Here, 'n' is the participants who were analyzed at specific time point.</population>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=3, 0 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.00" spread="5.686"/>
                    <measurement group_id="O2" value="NA">No participant was analyzed at this time point.</measurement>
                    <measurement group_id="O3" value="NA">Data was not estimable as plasma concentration was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n=3, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.33" spread="10.477"/>
                    <measurement group_id="O2" value="33.30">Only 1 participant was analyzed at this time point.</measurement>
                    <measurement group_id="O3" value="NA">Data was not estimable as plasma concentration was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tlqc): Mean Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-448F</title>
        <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
        <time_frame>Day 1 and Day 22 pre-dose and at multiple time points (up to 8 hours) post-dose</time_frame>
        <population>PK set included all participants who received at least one dose of study drug and had at least 1 measurable concentration of TAK-448F.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 3 µg Once Weekly</title>
            <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 1 µg Once Weekly</title>
            <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 0.3 µg Once Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlqc): Mean Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-448F</title>
          <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
          <population>PK set included all participants who received at least one dose of study drug and had at least 1 measurable concentration of TAK-448F.</population>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.23" spread="6.732"/>
                    <measurement group_id="O2" value="19.00" spread="3.470"/>
                    <measurement group_id="O3" value="NA">Data was not estimable as plasma concentration was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.20" spread="11.914"/>
                    <measurement group_id="O2" value="18.37" spread="3.069"/>
                    <measurement group_id="O3" value="NA">Data was not estimable as plasma concentration was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Terminal Phase Elimination Half-life (T1/2) for TAK-448F</title>
        <description>Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
        <time_frame>Day 1 and Day 22 pre-dose and at multiple time points (up to 8 hours) post-dose</time_frame>
        <population>Pharmacokinetic (PK) set included all participants who received at least one dose of study drug and had at least 1 measurable concentration of TAK-448F. Here, 'n' is the participants who were analyzed at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 3 µg Once Weekly</title>
            <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 1 µg Once Weekly</title>
            <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 0.3 µg Once Weekly</title>
            <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Terminal Phase Elimination Half-life (T1/2) for TAK-448F</title>
          <description>Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
          <population>Pharmacokinetic (PK) set included all participants who received at least one dose of study drug and had at least 1 measurable concentration of TAK-448F. Here, 'n' is the participants who were analyzed at specific time point.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=3, 0, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.800" spread="0.0751"/>
                    <measurement group_id="O2" value="NA">No participant was analyzed at this time point.</measurement>
                    <measurement group_id="O3" value="NA">Data was not estimable as plasma concentration was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n=3, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.073" spread="0.1920"/>
                    <measurement group_id="O2" value="1.150">Only 1 participant was analyzed at this time point.</measurement>
                    <measurement group_id="O3" value="NA">Data was not estimable as plasma concentration was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to Day 39</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAK-448 3 µg Once Weekly</title>
          <description>TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
        </group>
        <group group_id="E2">
          <title>TAK-448 1 µg Once Weekly</title>
          <description>TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
        </group>
        <group group_id="E3">
          <title>TAK-448 0.3 µg Once Weekly</title>
          <description>TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.</description>
        </group>
        <group group_id="E4">
          <title>TAK-448 0.3 µg Twice Weekly</title>
          <description>TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
        </group>
        <group group_id="E5">
          <title>TAK-448 0.1 µg Twice Weekly</title>
          <description>TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

